Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 467 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Testing Clear all
Completed Phase 2 Interventional

Clinical Evaluation of Bacitracin

NCT00132600
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
bacitracin (allergen)
Drug
Lead sponsor
Mekos Laboratories AS
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 18, 2005 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Challenges Without Prior Skin Testing

NCT03158831
View directory record Official record
Conditions
Drug Hypersensitivity, Penicillin Allergy, Antibiotic Allergy
Interventions
Placebo-Controlled Graded Drug Challenge
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
7 Years and older
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jun 26, 2026, 3:04 AM EDT
Suspended Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Phoenix, Arizona • Costa Mesa, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

NCT03798366
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Jun 26, 2026, 3:04 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Topical Safety Study of Topical Diltiazem Hydrochloride

NCT01816529
View directory record Official record
Conditions
Diltiazem Skin Sensitivity.
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution of sodium lauryl sulfate (SLS), Saline (0.9%)
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

NCT06369727
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Jun 26, 2026, 3:04 AM EDT
Terminated Phase 2 Interventional

Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer

NCT02008994
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Genomic and Proteomic Profiling
Other
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Jun 26, 2026, 3:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis

NCT00868842
View directory record Official record
Conditions
Anaphylaxis
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Phase 4 Interventional Results available

Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents

NCT00795951
View directory record Official record
Conditions
Dermatitis, Contact
Interventions
T.R.U.E. Test
Biological
Lead sponsor
Allerderm
Industry
Eligibility
6 Years to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Jun 26, 2026, 3:04 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

NCT01609062
View directory record Official record
Conditions
Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions
BMN 110
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Oakland, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Phase 1 Interventional Results available

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

NCT01730118
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu Expression
Interventions
Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation

NCT03861780
View directory record Official record
Conditions
Bacteria Microflora Reduction
Interventions
Project X 26ml, Project X 5.1ml, Prevantics Maxi Swabstick
Drug
Lead sponsor
Professional Disposables International, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Allergy Skin Patch Artificial Intelligence (AI)

NCT05339750
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
AI-based smartphone application, Allergen patch
Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Not applicable Interventional

Implementation of ABI and WIfI in Rural Health Clinics

NCT04337723
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetic Foot, Diabetes Mellitus
Interventions
ABI/WIFI scoring
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Jun 26, 2026, 3:04 AM EDT
Completed No phase listed Observational

Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations

NCT00579007
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
telephone interviews
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
25 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Jun 26, 2026, 3:04 AM EDT
Not listed No phase listed Observational

Breast Cancer Tumor Heterogeneity

NCT02108561
View directory record Official record
Conditions
Breast Cancer
Interventions
Post Surgical Her2 testing
Other
Lead sponsor
Anne Arundel Health System Research Institute
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Annapolis, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Phase 2 Interventional Results available

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

NCT02962960
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jun 26, 2026, 3:04 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Determination of Kidney Function

NCT00001978
View directory record Official record
Conditions
Kidney Disease, Proteinuria, Autoimmune / Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Not applicable Interventional Results available

Measuring and Improving the Safety of Test Result Follow-Up

NCT04166240
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Colon Cancer, Bladder Cancer, Hepatocellular Cancer
Interventions
SAFER TRACKS Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Houston, Texas • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jun 26, 2026, 3:04 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

NCT05947500
View directory record Official record
Conditions
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
Interventions
Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
50
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 26, 2026, 3:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Reactions in Contact Dermatitis Affected Skin

NCT01546298
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Patch tests
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

NCT00598832
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene lotion 0.1%, Adapalene Lotion Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,075 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Marina del Rey, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy

NCT00640614
View directory record Official record
Conditions
Contact Dermatitis
Interventions
T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Little Rock, Arkansas • Shawnee Mission, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Jun 26, 2026, 3:04 AM EDT
Completed Not applicable Interventional

Improving Surgical/Medical Oncology Collaboration for Breast Cancer Treatment Planning: Pilot Testing the Impact of Continuing Education and Patient Care Planning

NCT03161600
View directory record Official record
Conditions
Breast Cancer
Interventions
Carevive CPS
Behavioral
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Jun 26, 2026, 3:04 AM EDT